Business Description
Maze Therapeutics Inc
NAICS : 541720
SIC : 2836
ISIN : US5787841007
Total Employee Number:
141Description
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 6.8 | |||||
Equity-to-Asset | 0.85 | |||||
Debt-to-Equity | 0.13 | |||||
Debt-to-EBITDA | -0.44 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 10.38 | |||||
Beneish M-Score | 7.63 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -2.6 | |||||
3-Year EPS without NRI Growth Rate | 1.4 | |||||
3-Year FCF Growth Rate | 2.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -7.21 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 47.47 | |||||
9-Day RSI | 46.75 | |||||
14-Day RSI | 47.7 | |||||
3-1 Month Momentum % | 8.23 | |||||
6-1 Month Momentum % | -36.58 | |||||
12-1 Month Momentum % | 114.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 18.31 | |||||
Quick Ratio | 18.31 | |||||
Cash Ratio | 17.9 | |||||
Days Sales Outstanding | 365 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.1 | |||||
Shareholder Yield % | -18.84 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -728.06 | |||||
Net Margin % | -667.95 | |||||
EBITDA Margin % | -681.29 | |||||
FCF Margin % | -534.2 | |||||
OCF Margin % | -532.69 | |||||
ROE % | -37.29 | |||||
ROA % | -32.21 | |||||
ROIC % | -221.37 | |||||
3-Year ROIIC % | -422.61 | |||||
ROC (Joel Greenblatt) % | -503.76 | |||||
ROCE % | -35.15 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 10.22 | |||||
PS Ratio | 73.28 | |||||
PB Ratio | 3.33 | |||||
Price-to-Tangible-Book | 3.33 | |||||
EV-to-EBIT | -8.39 | |||||
EV-to-EBITDA | -8.51 | |||||
EV-to-Revenue | 57.96 | |||||
EV-to-Forward-Revenue | 59.21 | |||||
EV-to-FCF | -10.85 | |||||
| Price-to-Net-Current-Asset-Value | 4.41 | |||||
| Price-to-Net-Cash | 4.54 | |||||
Earnings Yield (Greenblatt) % | -11.92 | |||||
FCF Yield % | -7.08 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MAZE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Maze Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 20 | ||
| EPS (TTM) ($) | -2.52 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 94.19 | ||
| 14-Day RSI | 47.7 | ||
| 14-Day ATR ($) | 1.558057 | ||
| 20-Day SMA ($) | 27.886 | ||
| 12-1 Month Momentum % | 114.56 | ||
| 52-Week Range ($) | 12.81 - 53.65 | ||
| Shares Outstanding (Mil) | 55.55 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Maze Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Maze Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 84 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | 27.31 (+0.04%) | ||
| Guidance call for 2026 | 2026-06-10 08:40 | 23.93 (+0.34%) | ||
| General meeting for 2025 | 2026-06-08 09:00 | 24.27 (-4.71%) | ||
| Guidance call for 2026 | 2026-06-03 15:45 | 24.29 (-2.88%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 25.52 (-2.67%) | ||
| Annual report for 2025 | 2026-03-25 | 49.00 (+1.74%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-25 | 49.00 (+1.74%) | ||
| the TD Cowen 46(th) Annual Health Care Conference | 2026-03-04 10:30 | 44.18 (-0.81%) | ||
| Guidance call for 2026 | 2026-02-11 15:00 | 48.37 (+1.55%) |
Show
Entries
Maze Therapeutics Inc Frequently Asked Questions
What is Maze Therapeutics Inc(MAZE)'s stock price today?
The current price of MAZE is $27.18. The 52 week high of MAZE is $53.65 and 52 week low is $12.81.
When is next earnings date of Maze Therapeutics Inc(MAZE)?
The next earnings date of Maze Therapeutics Inc(MAZE) is 2026-11-06 Est..
Does Maze Therapeutics Inc(MAZE) pay dividends? If so, how much?
Maze Therapeutics Inc(MAZE) does not pay dividend.
Guru Commentaries on NAS:MAZE
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Maze Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers